乳腺癌组织中CHK2和pCHK2蛋白的表达及临床意义

Expression and Clinical Significance of CHK2 and pCHK2 in Patients of Breast Cancer

目的检测乳腺癌组织和癌旁组织中细胞周期检测点激酶2(CHK2)和磷酸化CHK2(pCHK2)蛋白的表达情况及其与乳腺癌临床病理学特征的相关性。方法制作乳腺癌组织芯片,利用免疫组化法检测261例乳腺癌组织及36例癌旁组织中CHK2和pCHK2蛋白的表达情况,并分析其与乳腺癌临床病理学特征的关系。结果 CHK2和pCHK2蛋白在癌组织中的表达分别为86.2%和24.1%,明显高于癌旁组织5.6%和0(P<0.05),且在同一病例的癌组织中表达呈正相关(r=0.226,P=0.023),CHK2和pCHK2与肿瘤病理类型、大小、淋巴结转移数目、TNM分期、ER、PR、Her-2等临床病理特征相关性无统计学差异(P>0.05)。结论 CHK2和pCHK2可能在乳腺癌的发生、发展中发挥着一定作用,可作为乳腺癌基因研究和治疗的靶点。

Objective To investigate the expression of CHK2 and pCHK2 in breast cancer and corresponding adjacent noncancerous tissue, and analyze the correlations between protein expression and its clinical significance. Methods Breast cancer tissue were collected to make tissue microarray. Immunohistochemieal technique was used to test CHK2 and pCHK2 expression in 261 patients breast camer and 36 corresponding adjacent noncancerous tissue. The relationship between clinical characteristic and CHK2/pCHK2 expression was also studied. Results CHK2 and pCHK2 protein expression in cancer tissues were 86.2% and 24.1% , which was significantly higher thar~ that in the adjacent tissues（5.6% and 0）. Their expression in cancer tissues were positively correlated （r = 0. 226, P = 0. 023 ）. There was no correlation between CHK2, pCHK2 distribution and clinieopathological parameters, such as TNM, ER, PR, Her - 2 （ P 〉 0.05 ）. Conclusion CHK2 and pCHK2 may play an important role in the development of breast cancer,and it may be considered as a valuable marker for the gene research and therapy of breast cancer.